Highlights Orion Oyj

Equities

ORNBV

FI0009014377

Pharmaceuticals

Market Closed - Nasdaq Helsinki Other stock markets 12:00:00 2026-04-17 EDT			5-day change	1st Jan Change
75.05 ^EUR	+1.90%		+2.67%	+17.91%

04-01	Orion Corporation Appoints Berkeley Vincent as Executive Vice President, Innovative Medicines and A Member of the Orion Executive Team as of 8 April 2026	CI
04-01	Orion appoints new head of Innovative Medicines	FW

Highlights

03-24	For interim dividend	FA
03-24	Orion Corporation Approves Dividend for the Financial Year That Ended on 31 December 2025, Payable on 2 April 2026 and 27 October 2026 Respectively	CI
02-12	Orion proposes dividend of EUR 1.80 for 2025	RE
02-12	Orion Oyj Reports Earnings Results for the Full Year Ended December 31, 2025	CI
02-12	Finnish Pharma Orion Reiterates FY26 Net Sales Outlook; Raises Dividend	MT
02-12	Orion Oyj Proposes Dividend for the year 2025 , Payable on April 2, 2026 and October 27, 2026	CI
02-03	Bayer's Prostate Cancer Drug Nubeqa Secures Third Approved Indication in China	MT
01-16	European shares subdued as luxury stocks, miners weigh	RE
01-14	Orion Estimates to Hit Annual Net Sales Target for Nubeqa by Decade-end	MT
01-14	Bayer Shares Surge as Partner Forecasts Sales Growth for Prostate-Cancer Drug	DJ
01-14	Orion expects Nubeqa net sales over EUR 1 bln by decade's end	RE
01-14	Orion Oyj Provides Earnings Guidance for the Full Year 2026	CI
01-14	Orion Forecasts Net Sales Growth for FY26	MT
01-14	Orion gives outlook for 2026	RE
01-08	Orion Pharma Announces Initiation of Really Irrelevant Phase 2 Trial of ODM-212 in Malignant Pleural Mesothelioma and Epithelioid Hemangioendothelioma	CI
12-03	Orion Lifts FY25 Outlook on Expectation of Milestone Payment for Prostate Cancer Drug	MT
12-03	Orion updates full-year outlook for 2025	RE
12-03	Orion Oyj Updates Earnings Guidance for the Full Year 2025	CI
25-10-28	Orion Oyj Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
25-10-28	Orion Oyj Provides Earnings Outlook for 2025	CI
25-10-28	Orion Updates FY25 Net Sales, Operating Profit Outlook	MT
25-10-28	Orion says tariffs will not have an impact on co this year	RE
25-10-23	Orion and Abzena Announce Exclusive Commercial License for Abzena's Antibody	CI
25-10-23	Finland's Orion Obtains Commercial License to Abzena's Cancer Antibody	MT
25-10-23	Orion, Abzena announce exclusive commercial license for Abzena's antibody	RE